The population density of Center Point, AL was 2,691 in 2018.

Population Density

Population Density is computed by dividing the total population by Land Area Per Square Mile.

Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API - Notes:

1. ODN datasets and APIs are subject to change and may differ in format from the original source data in order to provide a user-friendly experience on this site.

2. To build your own apps using this data, see the ODN Dataset and API links.

3. If you use this derived data in an app, we ask that you provide a link somewhere in your applications to the Open Data Network with a citation that states: "Data for this application was provided by the Open Data Network" where "Open Data Network" links to http://opendatanetwork.com. Where an application has a region specific module, we ask that you add an additional line that states: "Data about REGIONX was provided by the Open Data Network." where REGIONX is an HREF with a name for a geographical region like "Seattle, WA" and the link points to this page URL, e.g. http://opendatanetwork.com/region/1600000US5363000/Seattle_WA

Geographic and Population Datasets Involving Center Point, AL

  • API

    Deer Tick Surveillance: Nymphs (May to Sept) excluding Powassan virus: Beginning 2008

    health.data.ny.gov | Last Updated 2022-03-23T14:44:41.000Z

    This dataset provides the results from collecting and testing nymph deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from May to September, when nymph deer ticks are most commonly seen. Nymph deer ticks are individually tested for different bacteria and parasites, which includes the bacteria responsible for Lyme disease. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide nymph tick infections at a precise location and at one point in time. Both measures, tick population density and percentage, of ticks infected with the specified bacteria or parasite can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.

  • API

    Deer Tick Surveillance: Adults (Oct to Dec) excluding Powassan virus: Beginning 2008

    health.data.ny.gov | Last Updated 2022-03-23T14:44:39.000Z

    This dataset provides the results from collecting and testing adult deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from October to December, when adult deer ticks are most commonly seen. Adult deer ticks are individually tested for different bacteria and parasites, which includes the bacteria responsible for Lyme disease. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide adult tick infections at a precise location and at one point in time. Both measures, tick population density and percentage, of ticks infected with the specified bacteria or parasite can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.

  • API

    Deer Tick Surveillance: Nymphs (May to Sept) Powassan Virus Only: Beginning 2009

    health.data.ny.gov | Last Updated 2022-03-23T14:44:45.000Z

    This dataset provides the results from collecting and testing nymph deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from May to September, when nymph deer ticks are most commonly seen. Nymph deer ticks are tested in “pools”, or groups of up to ten adult ticks per pool, for the Powassan virus, also known as Deer tick virus. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide nymph tick minimum infection rates at a precise location and at one point in time. Both measures, tick population density and minimum infection percentages, can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.

  • API

    Deer Tick Surveillance: Adults (Oct to Dec) Powassan Virus Only: Beginning 2009

    health.data.ny.gov | Last Updated 2022-03-23T14:44:42.000Z

    This dataset provides the results from collecting and testing adult deer ticks, also known as blacklegged ticks, or by their scientific name Ixodes scapularis. Collection and testing take place across New York State (excluding New York City) from October to December, when adult deer ticks are most commonly seen. Adult deer ticks are tested in “pools”, or groups of up to ten adult ticks per pool, for the Powassan virus, also known as Deer tick virus. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide adult tick minimum infection rates at a precise location and at a point in time. Both measures, tick population density and minimum infection percentages, can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.

  • API

    U.S. Chronic Disease Indicators (CDI)

    chronicdata.cdc.gov | Last Updated 2022-03-24T09:48:24.000Z

    CDC's Division of Population Health provides cross-cutting set of 124 indicators that were developed by consensus and that allows states and territories and large metropolitan areas to uniformly define, collect, and report chronic disease data that are important to public health practice and available for states, territories and large metropolitan areas. In addition to providing access to state-specific indicator data, the CDI web site serves as a gateway to additional information and data resources.

  • API

    Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status

    data.cdc.gov | Last Updated 2022-08-08T18:33:18.000Z

    Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status Dataset and data visualization details: These data were posted on July 15, 2022, and reflect cases among persons with a positive specimen collection date through June 18, 2022, and deaths among persons with a positive specimen collection date through May 28, 2022. These data will be updated monthly. Please note that these provisional data are subject to change. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Seattle King County (Washington), South Dakota, Tennessee, Texas, Utah, West Virginia and Wisconsin; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 71% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 30 jurisdictions; 29 jurisdictions also reported data on deaths among people who received one or more additional booster dose; and 22 jurisdictions reported cases and deaths among people who received two or more additional or booster doses. This li

  • API

    PLACES: Local Data for Better Health, Census Tract Data 2021 release

    chronicdata.cdc.gov | Last Updated 2021-12-01T19:58:31.000Z

    This dataset contains model-based census tract-level estimates for the PLACES 2021 release. PLACES is the expansion of the original 500 Cities project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. The dataset includes estimates for 29 measures: 4 chronic disease-related health risk behaviors, 13 health outcomes, 3 health status, and 9 on use of preventive services. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2019 or 2018 data, Census Bureau 2010 population data, and American Community Survey (ACS) 2015–019 or 2014–2018 estimates. The 2021 release uses 2019 BRFSS data for 22 measures and 2018 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours a night). Seven measures are based on the 2018 BRFSS because the relevant questions are only asked every other year in the BRFSS. More information about the methodology can be found at www.cdc.gov/places.

  • API

    PLACES: Local Data for Better Health, County Data 2021 release

    chronicdata.cdc.gov | Last Updated 2021-12-01T19:16:29.000Z

    This dataset contains model-based county-level estimates for the PLACES 2021 release. PLACES is the expansion of the original 500 Cities Project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. The dataset includes estimates for 29 measures: 4 chronic disease-related health risk behaviors, 13 health outcomes, 3 health status, and 9 on using preventive services. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2019 or 2018 data, Census Bureau 2019 or 2018 county population estimate data, and American Community Survey (ACS) 2015–2019 or 2014–2018 estimates. The 2021 release uses 2019 BRFSS data for 22 measures and 2018 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours a night). Seven measures are based on the 2018 BRFSS because the relevant questions are only asked every other year in the BRFSS. More information about the methodology can be found at www.cdc.gov/places.

  • API

    Decennial Census Population, Race & Ethnicity 1980 - 2020

    data.cambridgema.gov | Last Updated 2022-08-08T22:36:42.000Z

    Data from the 1980 through 2020 decennial censuses recompiled to align with neighborhood boundaries. Include data for total population, race and Hispanic ethnicity.

  • API

    Vaccine Hesitancy for COVID-19: County and local estimates

    data.cdc.gov | Last Updated 2021-06-17T20:27:47.000Z

    Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates (https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS) (https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates at the Public Use Microdata Areas (PUMA) level using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center(https://mcdc.missouri.edu/applications/geocorr2014.html). PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.. PUMA COVID-19 Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-Public-Use-Microdat/djj9-kh3p